Stay updated on Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial

Sign up to get notified when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.5%
    Check dated 2025-06-06T10:02:57.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an opportunity for API users to provide input. The revision number has also been updated from v2.16.0 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-30T04:51:46.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.0, replacing the previous version 2.15.2.
    Difference
    0.6%
    Check dated 2025-05-23T02:16:13.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2025-05-15T21:11:23.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2025-05-08T13:54:41.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content or functionality of the page.
    Difference
    0.1%
    Check dated 2025-05-01T06:22:04.000Z thumbnail image

Stay in the know with updates to Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.